GSK plc has completed its previously announced acquisition of IDRx Inc., a Boston-based, clinical-stage biopharmaceutical ...

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...

GSK (GSK) plc announced that it has completed the acquisition of IDRx, Inc., a Boston-based, clinical-stage biopharmaceutical company dedicated ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.

and completed a $120 million Series B last August to fund clinical development of lead cancer drug candidate IDRX-42, which hiked its valuation to around $430 million. The company had also been ...

That pipeline is led by IDRX-42, a highly selective KIT tyrosine kinase inhibitor (TKI) that is being developed as a first- and second-line therapy for gastrointestinal stromal tumour (GIST ...

The financing involves the payment of an advance of $1 billion. The deal includes the acquisition of IDRX-42, a highly selective aTKI kit being developed as a first- and second-line therapy for the ...

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...